Researchers have discovered two genetically distinct HIV types in the cerebrospinal fluid of patients with HIV-associated dementia, which may predict disease progression and cognitive damage. The study found that one variant infects macrophages, a type of white blood cell, while the other reproduces in T cells.
Researchers have discovered a new class of compounds that stick to the sugary coating of the AIDS virus and inhibit its entry into cells. The synthetic lectins, developed from a compound called benzoboroxole, show promise as a potential microbicide to prevent HIV infection.
Researchers challenged online gamers to predict the structure of a protein-cutting enzyme from an AIDS-like virus using the game Foldit. The players successfully generated accurate models, which were refined and determined to be correct within days.
A team of gamers solved the molecular structure of a retrovirus enzyme using online game Foldit, achieving results in just three weeks. The breakthrough could lead to the development of new anti-AIDS drugs by targeting specific features on the molecule.
Researchers create cats with intrinsic immunity to feline AIDS by inserting protective protein genes. The technique, called gamete-targeted lentiviral transgenesis, also makes the offspring glow green for tracking purposes.
The Einstein College of Medicine consortium aims to collect and analyze data on nearly 40,000 patients with antiretroviral therapy (ART) in Burundi, Cameroon, and Rwanda. The project will help improve the care and lives of residents by providing a robust database for researchers to examine the real-world practice and results of ART.
Experts urge collective global effort to stem cardiovascular diseases, type 2 diabetes, and other major health challenges. A United Nations summit will draw on experiences from the HIV/AIDS pandemic, promoting research, prevention, and treatment efforts.
A new article in PLOS Medicine suggests that improvements in advocacy, national planning, resource allocation, long-term investments, and health system strengthening are needed to tackle non-communicable diseases. The authors argue that lessons learned from the global AIDS response can inform a successful NCD response.
A recent study from Duke University Medical Center reveals that Cryptococcus gattii is more commonly found in AIDS patients than previously thought. This distinction could lead to differences in treatment and clinical outcomes, as C. gattii may exhibit resistance to commonly used antifungal drugs.
The FDA has cleared a new diagnostic test that detects the cryptoccocal antigen, allowing for early diagnosis and treatment of cryptococcosis. The rapid blood test, known as the CrAg Lateral Flow Assay, is designed for resource-limited settings and can be administered in just a few minutes.
Researchers have isolated 17 novel antibodies capable of neutralizing a broad spectrum of HIV variants, offering new targets for vaccine candidates. The potency of these antibodies is significantly higher than previously discovered ones, with some blocking infection up to 100 times more effectively.
The article highlights the connection between neglected tropical diseases (NTDs) and HIV/AIDS, proposing ways to integrate NTD treatment programs with HIV/AIDS initiatives. Studies show that areas with high NTD infection rates also have high HIV/AIDS prevalence, and co-infections can exacerbate HIV/AIDS.
Researchers focus on HIV cure research, highlighting the need for proactive outreach programs to prevent transmission in injecting drug users. The conference also emphasizes the importance of improving maternal and child health in sub-Saharan Africa and Southeast Asia.
Researchers stress need for long-term response to AIDS, citing financing, retention, and socio-political instability as major challenges. Social scientists urged to take part in policy-making table.
The International AIDS Society will launch a Virtual Knowledge Centre to improve knowledge and strengthened operations research capacity for HIV/OST programmes in Eastern Europe and Central Asia. The centre aims to create an increased Russian-language evidence base around OST, harm reduction, and HIV.
Researchers call for integrated strategies to prevent HIV infection, building on progress in vaccine research and the development of a vaginal gel. A combination of biomedical and non-biomedical approaches is seen as crucial to address the evolving landscape of HIV prevention.
A large-scale study reveals that patients in Africa receiving cART for HIV can expect a near-normal lifespan, with females living longer than males. Early initiation of treatment is associated with longer life expectancy, highlighting the need for continued investment in HIV programming.
DNDi has launched a new programme to develop paediatric HIV treatments, focusing on improving dosing, tolerability and affordability. The initiative aims to fill the unmet treatment gap for millions of children with HIV/AIDS in low- and middle-income countries.
A five-year NIH grant will fund research at the Emory Vaccine Center and Yerkes National Primate Research Center to develop a safe and effective HIV vaccine. The goal is to understand how to prevent early stages of mucosal infection from simian immunodeficiency virus, a key step in developing an effective HIV vaccine.
The Rome Statement for an HIV Cure aims to accelerate HIV cure research by building a global consensus on the state of HIV reservoirs and defining scientific priorities. The strategy recognizes the importance of developing a safe, accessible, and scalable HIV cure as a therapeutic and preventive strategy against HIV infection.
Boston Medical Center has received a grant to expand its HIV/AIDS clinic and provide more comprehensive case management services. The new facility will enable collaboration between infectious diseases and primary care departments, improving the quality of care for patients with HIV/AIDS.
The International AIDS Society advocates for an expanded global HIV strategy that incorporates 'Treatment as Prevention' to reduce transmission and prevent the onset of AIDS. This approach promotes widespread HIV testing and facilitated access to free treatment for all medically eligible individuals.
The University of North Carolina will lead a national effort to find a cure for AIDS by developing ways to purge the latent HIV virus from patients' immune systems. The five-year grant aims to better understand where and how the virus is established, and how to eliminate it.
The Gladstone Institutes will explore the molecular basis of HIV latency and develop inhibitors against cellular proteins to potentially cure HIV-infected patients. The funding is part of the National Institute of Allergy and Infectious Diseases' Martin Delaney Collaboratory initiative.
The International AIDS Society announced six winners of prestigious scientific awards to be presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. These awards recognize innovative HIV research throughout the world, highlighting the challenges faced by women and girls in the epidemic.
A new mathematical model predicts the location of mutations that lead to HIV-drug resistance, providing a potential solution to improve anti-HIV drug design. The study suggests that understanding these physical properties and interactions can help develop better strategies for combating the virus.
The newest AIDS drug, Edurant, was developed by Rutgers scientists after 13-year collaboration with Janssen Pharmaceutica. The drug has shown exceptional potency against drug-resistant HIV, with 83% of trial participants having undetected HIV levels.
This observational cohort study found HAART markedly improves the survival of HIV-infected children in a severely resource-deprived country. The treatment's effectiveness was comparable to that seen in more affluent settings, addressing a significant need for information on its impact in low-income countries.
Researchers have found that people with HIV can be safely treated with cancer therapies without adverse interactions. The study, conducted by the AIDS Malignancy Consortium, explores potential interactions between highly active anti-retroviral therapy (HAART) and newer targeted cancer drugs.
AIDS-related cancer, Kaposi's sarcoma, is a frequent harbinger of HIV, with FSU scientist Dr. Fanxiu Zhu leading research on the human herpesvirus 8 (HHV-8) to develop targeted therapies. His work focuses on viral proteins, including ORF45, which plays a crucial role in infection and immune evasion.
A new HIV investment model is proposed to achieve a more targeted and strategic approach to HIV/AIDS funding. The model would require 30% more funding, estimated at $22 billion annually by 2015, to avoid 12.2 million new infections and 7.4 million deaths between 2011 and 2020.
Researchers aim to efficiently identify more HIV-infected people through expanded voluntary testing programs. They also seek innovative approaches to curing HIV/AIDS by eradicating or suppressing the virus in infected individuals.
Drs. Fauci and Dieffenbach emphasize the importance of antiretroviral therapy (ART) in controlling HIV transmission, with early treatment preventing 96% of transmission in a clinical trial. They also highlight the need for a cure and new biomedical prevention therapies to ultimately end the epidemic.
A new study by Henry Ford Health shows that patients with mild hearing loss are motivated to purchase hearing aids based on factors other than cost, including perception of need and insurance coverage. Despite significant advancements in hearing aid technology and comfort, many adults with mild hearing loss do not acquire devices.
Experts warn that disclosing quantitative data to patients can backfire due to numeracy problems and biases in interpreting data. Studies show that decision aids increase patient knowledge but may not always lead to informed decisions. Researchers advocate for further research on presenting risk information to aid decision-making.
The number of AIDS-defining cancers decreased, while non-AIDS-defining cancers increased significantly between 1991-2005. Lung cancer emerged as the most common malignancy in people with HIV but not AIDS.
A new study published by NCI and CDC found a significant shift in the distribution of cancers in the HIV/AIDS population. Cases of AIDS-defining cancers decreased threefold between 1991-95 and 2001-05, while cases of other cancers increased tripled during the same period.
Research reveals that people with AIDS have a significantly higher risk of developing stomach and esophageal malignancies, including a 6.9-fold increased incidence of stomach cancer and a 2.7-fold increased risk of esophageal cancer compared to the general population.
Scientists have engineered a protein fragment that prevents the AIDS virus from entering cells, offering a potential breakthrough in treating and preventing HIV/AIDS infection. The discovery is based on a naturally occurring protein called RANTES, which was modified to remove harmful effects while maintaining its therapeutic properties.
Researchers at Dana-Farber Cancer Institute have identified a promising target for an AIDS vaccine: the V3 loop of the virus's protein envelope. Immune system antibodies aimed at this loop may offer protection against multiple genetic subtypes of HIV-1, offering hope for a universally effective vaccine.
A study found that people with HIV/AIDS feel reluctant to disclose their disease due to subtle clues from their communities. The motivation for this reluctance varies among individuals, with some valuing tolerance and others responding to social pressure.
A Dartmouth HIV/AIDS study found that a protease inhibitor was working better than nevirapine among infants with no previous exposure to the popular anti-retroviral. The treatment could turn treatment 'on its head' in resource-limited countries, where cheaper alternatives are often preferred.
Researchers investigated the risks of starting antiretroviral therapy in HIV-infected patients with TB, finding that early ART may not reduce AIDS risk for those with fewer than 250 CD4+ T cells. Microbicide studies showed promise with rectally applied tenofovir gel reducing HIV infection risk in men and women.
Homeless kids who use online social networking sites are more likely to have been tested for sexually transmitted infections and better informed about preventing them, despite increased risk of risky behaviors
A new therapeutic vaccine has shown a significant response in the majority of AIDS patients, with a decrease in viral load. The vaccine, developed by the Hospital Clinic of Barcelona-IDIBAPS, uses patient's own dendritic cells and has achieved an improvement over previous initiatives.
A study of over 2,000 US patients found greater HIV/AIDS-related morbidity among women, nonwhites, and those from the southern US. The disparities were attributed to socioeconomic factors beyond biological influences.
Researchers found that anti-retroviral therapy improves household investments, education, and nutrition, while a prevention strategy focusing on girls reduces HIV prevalence and genital herpes. The 'Lazarus effect' suggests long-term treatment yields significant economic dividends and positive behavioral changes.
The US PLWHA death rate decreased from 1996-2006, with a sharp drop in AIDS-defining illnesses, while non-HIV related diseases like heart disease and liver disease increased, according to CDC analysis.
A study finds that South African children caring for AIDS-sick parents experience high levels of mental illness, including depression and anxiety. The young carers' education is also affected, with 41% missing school to care for their sick parents.
A recent study has found that media coverage on HIV/AIDS in developed countries has decreased by over 70% since the 1990s. Meanwhile, attention to climate change has increased significantly, potentially diverting resources away from addressing socioeconomic issues like malaria and poverty.
Dr. Douglas A. Jabs has been recognized by the American Academy of Ophthalmology with the Jackson Memorial Lecture for his decades-long study on cytomegalovirus retinitis and its interaction with HIV. His research aims to improve clinical outcomes in patients with AIDS and CMV retinitis.
The Lancet Review emphasizes the need for tailored approaches in HIV/AIDS financing, as countries face diverging challenges. High-burden low-income (HBLI) countries will likely require extended international support, while middle-income nations with lower burdens can sustain funding using domestic resources.
Researchers emphasize Couples Voluntary Counseling and Testing (CVCT) as a proven method to decrease HIV/AIDS rates in Africa. The approach identifies undiagnosed individuals, allowing for targeted interventions before new infections occur.
Researchers will investigate biological mechanisms of broadly neutralizing antibody generation and its relevance to AIDS vaccine design. The U19 grant will support studies using samples from HIV-positive volunteers worldwide.
Scientists at IRB Barcelona discover that raltegravir cancels function of essential protein in herpesvirus replication, offering potential target for new drug development. Human cytomegalovirus, the most deadly and widespread herpes virus, shows vulnerability to raltegravir treatment.
The NIH will fund a five-year research initiative to identify and treat HIV-positive inmates in the US prison system. The goal is to reduce HIV transmission and improve public health by linking those in incarceration to antiretroviral therapy and medical care.
Minister Tedros Adhanom Ghebreyesus advocates for 'country ownership' to maximize development aid impact. Countries must have clear vision and control over resources, allowing them to tailor proven practices to their specific circumstances.
The formation of AVAN, the AIDS Vaccine for Asia Network, aims to accelerate research and development of an AIDS vaccine through government advocacy and improved coordination. With over 5 million people infected and 500 million at risk, regional efforts must be strengthened to combat HIV in Asia.
HIV-1 virus uses ATP to remove AZT, a widely used AIDS treatment, allowing it to replicate itself. This discovery helps researchers understand why anti-AIDS treatments can fail, enabling the development of more effective treatments for HIV patients.
Researchers have discovered that a precursor to the AIDS-causing HIV is at least 32,000 years old, contradicting previous estimates. The study suggests that HIV's evolution into a non-lethal form is unlikely due to its rapid virulence.